In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug program. But for Valneva CEO Thomas Lingelbach, the regulatory future of the Pfizer-partner Lyme disease vaccine, VLA15, is very much “a matter of negotiation.”
- Home |
- Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole story
Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole story
- April 1, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
